![Three-day ODAC to review data from confirmatory trials of PD-1/PD-L1 drugs marketed under accelerated approval](https://cdn.cancerletter.com/media/2021/03/28073723/47-10-pazdur_4x3.jpg)
![Three-day ODAC to review data from confirmatory trials of PD-1/PD-L1 drugs marketed under accelerated approval](https://cdn.cancerletter.com/media/2021/03/28073723/47-10-pazdur_4x3.jpg)
Cover Story
FDA will hold a three-day meeting of the Oncologic Drugs Advisory Committee April 27-29 to consider five indications that received accelerated approvals, but that have not been shown to produce a clinical benefit in confirmatory trials.
In Brief
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
Trending Stories
- Before the Olympics were smoke-free, tobacco brand deals ran rampant
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications
- Jonathan Gerber named chief clinical officer of NYU Langone Health’s Perlmutter Cancer Center
- Tweaking the existing systems is not the answer to drug shortages